Avenue Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ATXI Nasdaq 2834 http://www.avenuetx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avenue Therapeutics Inc

Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference - Jun 19th, 2018 6:30 am
ATXI: KOL Call with Drs. Singla and Minkowitz on IV Tramadol - Jun 12th, 2018 7:30 am
Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain - Jun 6th, 2018 6:30 am
Blog Exposure - Avenue Therapeutics Reported Positive Results from Pivotal Phase-3 Trial of IV Tramadol - May 23rd, 2018 5:25 am
Benzinga Pro's 5 Stocks To Watch Today - May 21st, 2018 6:59 am
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain - May 21st, 2018 4:30 am
ATXI: 1Q:18 Update Confirms Timeline - May 14th, 2018 8:30 am
Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights - May 3rd, 2018 5:30 am
ATXI: No Pain? We See a Gain; Developing Tramadol - Apr 10th, 2018 11:20 am
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol - Mar 28th, 2018 6:00 am
Here's the Latest on Four New Biotech IPOs - Jul 3rd, 2017 11:02 am